CSIMarket Company Name, Ticker, Industry, else..
 
Ortho Clinical Diagnostics Holdings Plc  (NASDAQ: OCDX)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 479
 Employees -
 Revenues (TTM) (Millions $) -7
 Net Income (TTM) (Millions $) 54
 Cash Flow (TTM) (Millions $) 119
 Capital Exp. (TTM) (Millions $) 72

Ortho Clinical Diagnostics Holdings Plc
Ortho Clinical Diagnostics Holdings Plc is a global in vitro diagnostics company that specializes in developing and producing solutions for blood testing. The company provides a wide range of products and services for clinical laboratories, hospitals, and blood banks worldwide. Ortho Clinical Diagnostics focuses on delivering accurate and reliable results to improve patient care and help healthcare professionals make informed decisions. With a strong commitment to innovation and advanced technology, the company aims to transform the future of diagnostics and contribute to improving global health outcomes.


   Company Address: 1001 Route 202 Raritan 8869 NJ
   Company Phone Number: 218-8000   Stock Exchange / Ticker: NASDAQ OCDX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Achieve Life Sciences Inc

In Vitro and In Vivo Diagnostic Substances company, decline in the company performance throughout the most recent fiscal period

The investors have not assumed some changes at the business throughout the the October to December 31 2024 reporting season at the company. Yet, shareholders pay near attention to ACHVs' operating shortfall which came in at $-12.19 million, during the matching time.

Alpha Teknova Inc

Strong in double digits Top-line rise at the company amid the most recent fiscal period

For the financial fourth quarter of 2024 company decreased a loss per share of $-0.08 per share compare to $-0.25 a year before and EPS improved from $-0.15 per share from the preceding reporting period. The revenue grew in double digits by 17.263 % to $10.13 million from $8.64 million in the comparable reporting period a year before and sequentially revenue advanced by 11.419 % from $9.09 million. Alpha Teknova Inc s' top-line, improvement in the fourth quarter of 2024 compares positively to its In Vitro and In Vivo Diagnostic Substances sector contemporaries, which made on average 3.63 % revenue improvement during the matching time thus far.

Quidelortho Corp

Quidelortho Corp disclosed a reasonably quiet period, amid the financial fourth quarter of 2024

Lower revenue led to diminishing Returns in the most recent fiscal period, Revenue sunk by -4.686 % to $707.80 million and loss per share was at $-2.63 compared to $0.10 per share realized in the financial reporting period a year ago. In contrast to the the QDELs' scenario the on averageIn Vitro and In Vivo Diagnostic Substances industry, posted a revenue 7.24% growth from the fourth quarter of 2023 in the fourth quarter of 2024.

Celldex Therapeutics Inc

Fading Diminishing Returns at the In Vitro and In Vivo Diagnostic Substances company in the most recent fiscal period

For the most recent fiscal period Celldex Therapeutics Inc decreased a loss per share of $-0.55 per share compare to $-0.82 a year before and earnings per share improved from $-0.64 per share from the preceding quarter. The revenue dropped sharply by -71.557 % to $1.18 million from $4.13 million in the corresponding quarter a year before and sequentially Revenue Tumbled by -63.178 % from $3.19 million.

Intellia Therapeutics Inc

The company published Revenue of $12.874 million, in the fourth quarter of 2024

Intellia Therapeutics Inc disclosed $12.874 million, in Revenue in the October to December 31 2024 financial span.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com